Covaxin 77.8% effective against COVID-19: Lancet study


PTI, Nov 12, 2021, 9:49 AM IST

Hyderabad: Bharat Biotech’s vaccine Covaxin has demonstrated that it is 77.8 per cent effective against symptomatic Covid-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group, Phase III data published in The Lancet said on Friday.

The efficacy data which was peer reviewed also said the vaccine demonstrated 63.6 per cent protection against asymptomatic Covid-19 and 65.2 per cent safety against the Delta variant besides showing 70.8 per cent guard against all variants of SARS-CoV-2 virus.

The efficacy analysis demonstrated that Covaxin to be 93.4 per cent effective against severe symptomatic Covid-19.

”The peer-review of Covaxin phase III clinical trial data in The Lancet, an authoritative voice in global medicine validates our commitment to data transparency and meeting the stringent peer-review standards of world leading medical journals.” ”The data from our product development and clinical trials have been published in 10 peer-reviewed journals, making Covaxin one of the most highly published COVID-19 vaccines in the world. This accomplishment reflects the undeterred commitment by my team members at Bharat Biotech, our public partners, Indian Council of Medical Research, National Institute of Virology, and the trust imposed by our trial participants who made this happen,” Bharat Biotech Chairman Krishna Ella said in a statement.

The phase 3 trial Efficacy and Safety Study involving 25,800 volunteers across 25 sites in India is India’s largest ever clinical trial conducted for a Covid-19 vaccine.

Balram Bhargava, Director General, Indian Council of Medical Research (ICMR) said, following successful isolation of the SARS-CoV-2 virus at NIV, ICMR and Bharat Biotech embarked upon one of the most successful public-private partnerships to develop the virus isolate into an effective COVID-19 vaccine. ”I am delighted to see that the phase III efficacy data has also been published in The Lancet, one of the most reputed journals worldwide. This itself speaks high about the strong position of Covaxin amongst other global front-runners COVID-19 vaccines,” Bhargava said.

The bench to bedside journey of Covaxin in less than 10 months showcases the immense strength of ”Atmanirbhar Bharat” along with the Indian academia and industry in fighting against the odds and carving a niche in the global community, he added.

Recently, the World Health Organisation granted emergency use listing to Covaxin, enabling countries to expedite their regulatory approval to import and administer doses.

The jab has also received emergency use authorisations in several countries with applications in process in more than 50 countries worldwide.

Bharat Biotech has partnered with Ocugen to obtain approvals for Covaxin in the United States and Canada.

With more than 150 million doses manufactured, supplied, and with an excellent safety and efficacy profile, Covaxin is a major contributor to the global fight against the COVID-19 pandemic, the statement said.

Covaxin is currently being evaluated in controlled clinical trials in children 2-18 years of age, with results available during Q4 2021.

Bharat Biotech is poised to achieve its goal of an annualised capacity of about 1.0 billion doses of the jab by the end of 2021.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

Aussies Hijikata, Kubler win Australian Open men’s doubles

Rashtrapati Bhavan’s Mughal Gardens renamed ‘Amrit Udyan’ to open for public from January 31

Sabalenka beats Rybakina for Australian Open women’s title

Grand inauguration of Kaustubha Residency – hotel & commercial complex at Katapady on Jan 29

Karnataka: Amit Shah takes part in road show in Kundgol, hits out at Cong and JD(S) for dynasty politics

DU forms 7-member panel to probe ruckus outside Arts Faculty over BBC documentary screening

One pilot killed in IAF’s Sukhoi, Mirage aircraft crash in MP


Related Articles More

Children’s ‘rushed’ immune response makes them susceptible to Covid reinfection: Study

Dr Reddy’s Lab launches generic eye treatment medication in US

New blood test can detect Alzheimer’s 3.5 years before diagnosis

Poor literacy linked to worse mental health problems: Study

Mandaviya launches Bharat Biotech’s nasal Covid vaccine

MUST WATCH

Villagers election boycott warning for road

Sand art | Malpe Beach Uthsava 2023 | Udupi – Udayavani

Various competitions, activities in Beach Utsava!

Melody King Rajesh Krishnan

Shakalaka Boom Boom Movie Review| |Premier Show Manipal


Latest Additions

Aussies Hijikata, Kubler win Australian Open men’s doubles

Attempts being made to create differences among people, ‘mantra of unity’ is ultimate antidote: PM Modi

2 held for cheating people on pretext of selling iphones on discounted rates

BJP releases list of 48 candidates for Tripura Assembly polls

Counsel ‘decourted’ for donning jeans in Gauhati HC

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.